Strategic collaborations

In January 2016, we entered into a collaboration agreement with MSD (known as Merck in the US and Canada) to run a Phase 2a study in pancreatic cancer using the combination of motixafortide and Merck’s KEYTRUDA®. We initiated this study in the second half of 2016 with the objective of demonstrating that the combination of drugs has the potential to expand the benefit of immunotherapy to cancer types currently resistant to immuno-oncology treatments. In July 2018, we announced the expansion of the COMBAT/KEYNOTE-202 study under the collaboration to include a triple combination arm investigating the safety, tolerability and efficacy of motixafortide, KEYTRUDA and chemotherapy. Results from this study were published in December 2020.


We are committed to the identification, in-licensing and systematic development of promising therapeutic candidates. Via in-licensing initiatives, we are eager to evaluate therapeutic frontiers in late-preclinical and clinical stages of development with an emphasis on ...

View In-Licensing


We seek to collaborate with leading global pharmaceutical companies with a proven track record in clinical experience, for completion of the final phases of the clinical trials, and commercial capabilities, to successfully bring our innovative ...

View Out-Licensing